ivermectin (stromectol) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ivermectin is a broad-spectrum anti-parasite medication. It was first marketed under the name Stromectol® and used against worms (except tapeworms), but, in 2012, it was approved for the topical treatment of head lice infestations in patients 6 months of age and older, and marketed under the name Sklice™ as well. Ivermectin is mainly used in humans in the treatment of onchocerciasis but is also effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis, and enterobiasis). Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria. This binding causes an increase in the permeability of the cell membrane to chloride ions and results in hyperpolarization of the cell, leading to paralysis and death of the parasite. Ivermectin also is believed to act as an agonist of the neurotransmitter gamma-aminobutyric acid (GABA), thereby disrupting GABA-mediated central nervous system (CNS) neurosynaptic transmission. Ivermectin may also impair the normal intrauterine development of O. volvulus microfilariae and may inhibit their release from the uteri of gravid female worms. It is sold under brand names Heartgard, Sklice and Stromectol in the United States, Ivomec worldwide by Merial Animal Health, Mectizan in Canada by Merck, Iver-DT in Nepal by Alive Pharmaceutical and Ivexterm in Mexico by Valeant Pharmaceuticals International. In Southeast Asian countries, it is marketed by Delta Pharma Ltd. under the trade name Scabo 6.   NCATS

Chemistry

  • SMILES: CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]3C[C@@H](C\C=C(/C)\[C@@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C\6/CO[C@@H]7[C@H](O)C(=C[C@@H](C(=O)O3)[C@]67O)C)O2.CO[C@H]8C[C@H](O[C@H]9[C@H](C)O[C@H](C[C@@H]9OC)O[C@H]%10[C@@H](C)\C=C\C=C\%11/CO[C@@H]%12[C@H](O)C(=C[C@@H](C(=O)O[C@H]%13C[C@@H](C\C=C\%10/C)O[C@@]%14(CC[C@H](C)[C@H](O%14)C(C)C)C%13)[C@]%11%12O)C)O[C@@H](C)[C@@H]8O
  • InChIKey: SPBDXSGPUHCETR-JFUDTMANSA-N
  • Mol. Mass: 1736.18
  • ALogP: Missing data
  • ChEMBL Molecule:
    ivermectin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$3.4074

United States

$3.4405 - $32.4600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

22,23-dihydro-5-o-demethylavermectin a1a | 22,23-dihydroavermectin b1a | 22,23-dihydroavermectin b(1)a | 22,23-dihydroavermectin b1(a) | ai3-29390-x | cardomec | dihydroivermectin b1a | eqvalan | h2b1a avermectin | heartguard | ivermectin | ivermectina | ivermectin component b1a | ivermectine | ivermectinum | ivmpo4 | ivomec | mectizan | noramectin | noromectin | sklice | stromectol | zimecterin

Organizations (239)

Research & Development (232)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (50)

Approved Indications (3)


 

Onchocerciasis (approved 1998)

Rosacea

Strongyloidiasis (approved 1998)

Experimental Indications - Clinical Trial Phases 1-4 (50)


 

Acne Vulgaris (Phase 2)

Alcoholism (Phase 1/Phase 2)

Anosmia (Phase 2/Phase 3)

Ascariasis (Phase 3)

Asymptomatic Infections (Phase 4)

Blepharitis (Phase 3)

Breast Neoplasms (Phase 2)

Coronavirus Infections (Phase 3)

COVID-19 (Phase 4)

Dengue (Phase 2/Phase 3)

Dermatitis, Atopic (Phase 2)

Drug Combinations (Phase 1)

Elephantiasis, Filarial (Phase 4)

Epilepsy (Phase 4)

Eye Diseases (Phase 1)

Healthy Volunteers (Phase 4)

Helminthiasis (Phase 4)

Hookworm Infections (Phase 3)

Impetigo (Phase 4)

Infections (Phase 3)

Infectious Disease Transmission, Professional-to-Patient (Phase 3)

Ivermectin (Phase 4)

Lice Infestations (Phase 3)

Loiasis (Phase 4)

Malaria (Phase 4)

Malaria, Falciparum (Phase 3)

Neoplasms (Phase 2)

Olfaction Disorders (Phase 2/Phase 3)

Onchocerciasis (Phase 4)

Onchocerciasis, Ocular (Phase 2)

Parasitic Diseases (Phase 3)

Pediculus (Phase 3)

Pharmacokinetics (Phase 3)

Pneumonia (Phase 4)

Poisoning (Phase 1/Phase 2)

Rosacea ()

Safety (Phase 1/Phase 2)

SARS-CoV-2 (Phase 4)

Scabies (Phase 4)

Severe Acute Respiratory Syndrome (Phase 2)

Severe acute respiratory syndrome-related coronavirus (Phase 3)

Severe Dengue (Phase 2)

Strongyloides (Phase 3)

Strongyloidiasis (Phase 3)

Trachoma (Phase 4)

Trichuriasis (Phase 3)

Tropical Medicine (Phase 3)

Wounds and Injuries (Phase 2)

Wuchereria bancrofti (Phase 1)

Yaws (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 198
  • # of Trial Organizations: 232

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue